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Background
Juvenile Polyposis Syndrome (JPS) is defined by the pre-
sence of ≥ 5 colorectal juvenile polyps or any number of
juvenile polyps in an individual with a family history of
JPS. Genetic alterations including either point mutations
or large rearrangements in BMPR1A or SMAD4 are
found in 50% of affected individuals. Hereditary Hemor-
rhagic Telangiectasia (HHT) is an autosomal dominant
disease diagnosed upon the presence of epistaxis, visceral
arteriovenous malformations (AVM) or mucutaneous tel-
angiectasias. HHT is diagnosed when there are ≥ 3 mani-
festations and is suspected when there are at least 2
manifestations. Most HHT cases are caused by a germ-
line mutation in ALK1 or ENG,m e m b e r so ft h eT G F b
signaling pathway. Approximately 22% of patients with
Juvenile Polyposis Syndrome (JPS) due to a SMAD4
mutation have been reported to also have HHT [1]. Most
prior publications have few patients and no systematic
approach to screening, so the true incidence of the com-
bined JPS/HHT syndrome is not known. Our aim was to
determine the prevalence of HHT in our patients with
JPS with a SMAD4 mutation including those who under-
went systematic screening for AVM’s.
Methods
JPS patients were identified from a comprehensive polypo-
sis database using Cologene© software. Families carrying a
germline SMAD4 mutation were studied by screening
affected patients for cutaneous telangiectases and with
cardiac bubble ECHO, CAT scan chest, or MRI of brain
for other AVMs.
Results
Fourteen of 38 JPS families underwent genetic testing.
Nine families were identified to have a SMAD4 muta-
tion. These families include 21 affected relatives,
11 men and 10 women, with a current mean age of
36.3 years (range 4 - 70). Fourteen affected relatives,
from 6 families, underwent HHT screening (7 men
and 7 women, with a mean age of 35.4 years (range
15-70). Eleven of 14 (79%) had ≥ 3 HHT manifesta-
tions and two of 14 (14 %) had at least 2. In addition,
3 of 7 unscreened affected relatives have presented
with at least 2 manifestations of HHT. Of the
24 families that have not had genetic testing or HHT
screening one affected family member presented with
≥ 3 HHT manifestations, and two had at least 2
manifestations.
Conclusion
Greater than 90% of our patients with JPS due to
SMAD4 mutations had clinically diagnosed or suspected
HHT. Genetic testing should be performed in all JPS
patients. In addition, systematic HHT screening is
recommended for JPS patients with SMAD4 mutations.
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